



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE



Innogenetics to distribute AdnaGen's CE-marked kits for breast and colon cancer in Europe

Ghent, Belgium, and Langenhagen, Germany, – January 29, 2007 – 18h00 – Innogenetics N.V. and AdnaGen AG announced today that they have entered into an exclusive European distribution agreement for AdnaGen's proprietary CE-certified diagnostics, the AdnaTest products for breast and colon cancer. The tests are based on the selection of circulating tumour cells from blood and subsequent detection of tumour markers. In parallel, Innogenetics also concluded a feasibility agreement to convert the current gel-based AdnaTest products into an *in-vitro* multiplex platform and an option and exclusive license agreement to commercialize these new multiplex tests worldwide.

Cancer diagnostics is a fast evolving and rapidly growing segment of *in-vitro* diagnostics. The high prevalence and mortality rates rank cancer amongst the world's most disabling and deadly diseases. Following cardiovascular disorders, cancer is the second most deadly condition, affecting over 25 million people worldwide, with more than 10 million new cases diagnosed worldwide annually. Approximately 260,000 people were diagnosed with colon cancer, and breast cancer was diagnosed in approximately 261,000 people in Europe in 2002. Furthermore, the cost of treating cancer is putting a serious pressure on global healthcare budgets. These data prime the need for improved diagnostics that either provide a diagnosis at an earlier stage or assist in better therapy management.

The AdnaTest products for breast and colon cancer are tools aiming at improved cancer prognosis and patient management. The tests rely on immunomagnetic selection of tumour cells from blood followed by detecting tumour specific markers using RT-PCR based molecular diagnostic techniques. The proprietary AdnaGen approach has the clear advantage that it does not solely rely on the detection of a single marker, but allows the detection of a broad range of tumour markers.

The AdnaTest can be applied on three distinct cancer diagnostic areas. The first is a better prognosis through the identification of circulating tumour cells as a measure of elevated risk of tumour metastases. Secondly, the detection of circulating tumour cells provides an indication of the treatment efficacy. Re-occurrence of circulating tumour cells may require prolongation of the treatment or seeking alternatives. Finally, the detection of circulating tumour cells months after therapy may indicate that the treated or resected tumour is relapsing.

Innogenetics also concluded a feasibility agreement and an option to a worldwide exclusive license agreement with AdnaGen. According to the feasibility agreement, Innogenetics will evaluate and develop alternatives to the current gel-based technique and convert them into other multiplex formats accustomed in the *in-vitro* diagnostics industry such as the well-established LiPA platform, or 4-MAT™.

In case Innogenetics successfully converts the current gel-based technology to a multiplex technology, Innogenetics has the option to a worldwide exclusive license for the commercialization of these newly developed tests.

Frank Morich, CEO of Innogenetics commented: *"This new agreement stresses yet again our determination to exploit new and emerging fields in molecular diagnostics. Detecting circulating tumour cells provides physicians a means to monitor therapy. Since cancer is evolving from a fatal condition towards a chronic disorder, Innogenetics wants to position itself to offer tools for improved patient management as well as cost control."*

Winfried Albert, Managing Director of AdnaGen remarked: *"We are very pleased that Innogenetics will be AdnaGen's partner in distributing our proprietary tumour diagnostics and to further develop our tests for their own platforms. Innogenetics has proven already its competence in bringing novel diagnostics successfully into the *in-vitro* diagnostics market. We are convinced that the partnership with Innogenetics is bound to become a success."*



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE



About AdnaGen

AdnaGen, founded in 1999, is a privately held biotechnology research and development company based in Langenhagen, Germany. As of 2005 OncoVista Inc. USA, an oncology drug development company is the majority owner of AdnaGen. AdnaGen focuses on the development of innovative tumour diagnostics by utilizing its proprietary technology for the detection and analysis of rare cells. Kits for metastatic breast and colon cancer are CE-marked and currently marketed in Europe. AdnaGen is DIN EN ISO 9001:2000 and DIN EN ISO 13485:2003 certified. For more information, go to www.adnagen.com.

About Innogenetics

Innogenetics is an international biopharmaceutical company building parallel businesses in the areas of specialty diagnostics and therapeutic vaccines.

In 2005, total revenues (product sales, royalties, and license fees) reached €48.6 million, with a profitable Specialty Diagnostics Division. Its Diagnostics Division develops a large number of specialty products covering three areas: infectious diseases (hepatitis C, hepatitis B, and HIV), genetic testing (HLA tissue typing and cystic fibrosis), and neurodegeneration (Alzheimer's disease). In its Therapeutics Division, Innogenetics focuses on the development of therapeutic vaccines to address unmet medical needs in the field of infectious diseases, with two compounds now in clinical trials (hepatitis C in phase IIb and hepatitis B in phase I).

Founded in 1985, Innogenetics is listed on Euronext Brussels [Ticker: INNX]. Innogenetics' headquarters are in Gent, Belgium, with sales subsidiaries in France, Germany, Italy, Spain, Brazil, and the United States. Innogenetics employs 510 people worldwide and has a market capitalization of approximately €265 million.

For further information, please contact:

Innogenetics

Dr. Filip Goossens
Tel.: +32 (0)9 329 1639
E-mail: investor_relations@innogenetics.com
Web: www.innogenetics.com
BTW BE 0427.550.660 RPR Gent

AdnaGen AG

Dr. Winfried Albert
Tel.: +49 (0)511 72595050
E-mail: wa@adnagen.com
Web: www.adnagen.com
HRB 58937, AG Hannover

Forward looking statement

This press release contains forward-looking statements that involve risks and uncertainties, including but not limited to projections of future revenues, operating income, and other risks. Prospective investors should be aware that these statements are estimates, reflecting only the judgments and projections of Innogenetics' management, and no undue reliance should be placed on such forward-looking statements.